Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market
Executive Summary
By granting an approval four months ahead of schedule of Roche AG's and Genentech Inc.'s anti-PD-LI cancer immunotherapy Tecentriq (atezolizumab), the FDA may have helped the companies secure a better lead in the bladder cancer marketplace than the firms otherwise would have held. But already established immunotherapies, Merck & Co. Inc.'s Keytruda (pembrolizumab) and Bristol-Myer Squibb Co.'s Opdivo (nivolumab), are in hot pursuit.
You may also be interested in...
Tecentriq Plus Chemo Data Could Re-Enforce Roche's Position In Bladder Cancer
Roche's PD-L1 inhibitor Tecentriq in combination with chemotherapy improved progression-free survival in first-line bladder cancer, after the immunotherapy failed a confirmatory trial as monotherapy.
Roche's Tecentriq Steals Lead In Triple-Negative Breast Cancer
The PD-L1 inhibitor is the first checkpoint immunotherapy to gain approval in the tough-to-treat disease setting.
Quick Commercial Standouts Lacking Among 2016 US Launches
The number of novel drugs approved by FDA in 2016 was down versus prior years, and many of the drugs that did launch are off to a slow start. The expectation is increasingly for drugs to build sales over time.